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Abstract
Spinal muscular atrophy (SMA) is the most common genetically inherited neurodegenerative disease that leads to infant mortality worldwide.
SMA is caused by genetic deletion or mutation in the survival of motor neuron 1 (SMN1) gene, which results in a deficiency in SMN protein. For
reasons that are still unclear, SMN protein deficiency predominantly affects α-motor neurons, resulting in their degeneration and subsequent
paralysis of limb and trunk muscles, progressing to death in severe cases. Emerging evidence suggests that SMN protein deficiency also affects
the heart, autonomic nervous system, skeletal muscle, liver, pancreas and perhaps many other organs. Currently, there is no cure for SMA. Patient
treatment includes respiratory care, physiotherapy, and nutritional management, which can somewhat ameliorate disease symptoms and increase
life span. Fortunately, several novel therapies have advanced to human clinical trials. However, data from studies in animal models of SMA indicate
that the greatest therapeutic benefit is achieved through initiating treatment as early as possible, before widespread loss of motor neurons has
occurred. In this review, we discuss the merit of carrier and perinatal patient screening for SMA considering the efficacy of emerging therapeutics
and the physical, emotional and financial burden of the disease on affected families and society.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive
disease, which affects approximately 1 in 10,000 live births and
has a carrier frequency of 1 in 40 people [1–3]. The hallmark of
the disease is degenerative loss of α-motor neurons in the brain
stem and spinal cord leading to progressive weakness of bulbar,
trunk and limb muscles, and eventually paralysis in severe
forms of the disease [3–5]. Thoracic cage deformation and
respiratory muscle weakness can lead to respiratory failure,
which frequently results in death, particularly in early onset
cases which are typically more severe [6]. SMA causes the
death of more infants than any other genetic disorder and is
currently incurable [1,4].Appropriately, this disease is the focus
of numerous disease pathology and therapeutic research
laboratories all over the world.
2. SMA genetics and disease severity
2.1. Genetic basis of SMA
SMA is caused by deletion or mutation of the survival of
motor neuron 1 (SMN1) gene found on chromosome 5q in
band 13 [7,8]. Homozygous deletion of SMN1 occurs in
approximately 95% of patients with SMA 5q13 [8], with the
remainder displaying a heterozygous state in which one SMN1
allele is deleted and the other contains a non-synonymous
mutation, or more rarely two SMN1 alleles that both contain
intragenic mutations [9]. The functional loss of SMN1 results in
a deficiency of SMN protein; however the protein is not
completely absent in affected patients due to the presence of
SMN2, a second SMN gene also present on 5q13 [7]. The SMN2
gene differs from SMN1 by five nucleotides [7], but only one of
these point mutations occurs in a coding region: the cytosine
found at position +6 of exon 7 in SMN1 is a thymidine in SMN2
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[10]. Although this is a silent transition in terms of the amino
acid encoded, the change to thymidine at this position results in
a dramatic alteration in pre-mRNA splicing, such that exon 7 is
excluded from ~90% of SMN2 mature transcripts [11]. The
protein generated from this alternatively spliced transcript,
termed SMNΔ7, is unable to fulfill the functional roles of full-
length SMN protein. A relatively small amount of full-length
SMN protein is generated from the 10% of SMN2 transcripts
that include exon 7 [11]. No patients have been identified who
have deletions or functional loss of both SMN1 and SMN2 [7],
suggesting that loss of both genes results in embryonic lethality
[12,13]. Mice encode only one Smn gene, and homozygous
deletion of this gene is embryonic lethal [12]. In the absence
of SMN1, the full-length SMN protein generated from SMN2
is sufficient to prevent embryonic lethality but not sufficient
to prevent the degeneration of α-motor neurons and the
subsequent presentation of SMA. In general, disease severity is
inversely correlated with the copy number of SMN2 [14,15].
Multiple hypotheses exist regarding the mechanism by
which the cytosine to thymidine change at position +6 of exon
7 causes its exclusion from the final transcript. Because this
exon features weak splicing sites at both the 3′ and 5′ ends [16],
proper inclusion of the exon is dependent on cis elements –
DNA regions which are recognized by trans-acting splicing
proteins and thereby enhance the inclusion or exclusion of a
given element in a transcript. These elements include intronic
splicing enhancers (ISEs), intronic splicing silencers (ISSs),
exonic splicing enhancers (ESEs), and exonic splicing silencers
(ESSs). At least one cis element from each category is believed
to be involved in splicing of exon 7 in SMN2 [17–25]. Thus, one
therapeutic approach currently under development is targeting
these various elements to enhance the probability of inclusion
of exon 7 in pre-mRNA derived from SMN2 (discussed below).
2.2. Variable severity and disease types
Patients with SMA are categorized into one of five types,
depending on age of disease onset, peak motor function
achieved, and life expectancy (Table 1) [28]. However, it is
generally recognized that SMA presents as more of a
continuum of phenotypes rather than discrete types [29]. Type 0
is characterized by congenital onset, respiratory distress at
birth, and very low life expectancy. This type of SMA is
generally immediately fatal if the patient does not receive
respirator support at birth. Type 1, known as Werdnig–
Hoffmann disease, presents before six months of age. Patients
with type 1 SMA are unable to sit independently and life
expectancy is less than two years [30]. In type 2, onset typically
occurs between 6 and 18 months of age. These patients are able
to sit independently but never achieve the ability to walk, and
have life expectancies between 10 and 40 years. Patients with
type 3, known as Kugelberg–Welander disease, experience
disease onset after 18 months and ultimately achieve the ability
to walk. Patients with type 4 SMA typically present as adults,
exhibit wide phenotypic variability, and retain the ability to
walk [31]. Types 3 and 4 are not usually associated with a
reduced life expectancy [26]. For a historical perspective on the
early identification of SMA, please see Reference [32].
Several groups have performed detailed observational
studies on disease progression in patients with SMA types 1, 2
and 3 [33–37]. Natural history studies provide much needed
information on the course of disease progression, which can aid
in assigning appropriate clinical outcome measures in human
trials of novel investigational approaches to SMA treatment or
management. In general, the highest motor function achieved
by a patient with SMA is more highly correlated to prognosis
than age of onset [33]. Among patients with similar ages of
onset, those who achieved the ability to sit or to walk
independently lived longer than those who did not [33].
SMA type and prognosis are generally inversely correlated
to the number of copies of the SMN2 gene, an important
modifier of disease severity [14,15,38]. The SMN locus is
variably amplified and, in patients with increased SMN2 copy
number, an additive effect occurs in which the combined full-
length transcript derived from each copy of the gene brings the
patient closer to the levels of SMN present in an unaffected
person. Quantitative PCR analysis performed by Feldkötter
et al. determined the SMN2 copy number of 375 patients with
SMA of known type [27]. From these data, the authors
generated percentage ratios that approximate the likelihood of
each SMA subtype when the SMN2 copy number is known
(Table 1) [27]. For example, the likelihood of an affected child
with only one copy of SMN2 acquiring type 1 SMA is greater
than 99.9%.With two copies of the gene, the probability of type
1 SMA is 97.26%, while the probabilities of type 2 and type 3
are 2.7% and 0.04%, respectively. With 3 or 4 copies of the
SMN2 gene, the patient is most likely to have type 2 and type 3
SMA, respectively (note: this study was not designed to detect
more than 4 copies of SMN2). However, this study suggests that
Table 1
Clinical types of spinal muscular atrophya.
Type Age of onset Characteristic motor function Life expectancy Probability by copy number of SMN2 (%)
1 2 3 4
0 Before birth Reduced movement in utero Fatal at birth –b – – –
1 <6 months Unable to sit unsupported <2 years >99.9 97.3 7.2 1.6
2 6–18 months Independent sitting 10–40 years <0.01 2.7 82.8 14.8
3 >18 months Independent walking Normal <0.01 0.04 10.0 83.6
4 >5 years Normal walking Normal – – – –
a Data from Russman [26] and Feldkötter [27], with modification.
b A dashed line indicates that data were not collected for this type.
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SMN2 copy number is an imperfect predictor of phenotypic
severity, particularly if the screen does not account for
intragenic mutations within some copies of SMN2 or
incomplete duplications. For example, patients with 4 copies of
SMN2 can present with anywhere from type 1 to type 4 disease
[27,39]. There are other genetic modifiers of SMA disease
severity, such as SERF1A and PLS3 [40–42], which further
confounds a prediction of disease severity based solely on
SMN2 copy number (of note, the role of PLS3 as a modifier of
SMA disease severity has not been supported in some mouse
models of SMA [43]). Thus, clinical assessment of peak motor
function still provides one of the best predictors of disease
severity and life expectancy.
3. SMN protein, putative functions and cell types affected
The SMN protein is 38 kDa in size, is ubiquitously
expressed, and is found in both the cytoplasm and the
nucleus [44,45]. Full-length SMN protein self-oligomerizes via
association of a 30-amino acid domain encoded by exon 6, and
missense mutations within or immediately adjacent to this
domain inhibit the ability of the protein to self-associate [46].
The SMNΔ7 protein produced from the SMN2 gene
shows a greatly reduced ability to self-associate [46]. Following
self-oligomerization, nuclear SMN is recruited into a
macromolecular complex containing Gemin proteins. The
formation of this complex appears to have a stabilizing effect
on the SMN protein, and failure to self-oligomerize or to be
recruited into these complexes may in part explain the reduced
half-life of SMNΔ7 protein compared to the full-length protein
[47]. The SMN complex is composed of SMN and Gemins 2
through 8 [48], and is found in subnuclear structures known as
gems. The name is derived from Gemini, as the nuclear
structures resembled twins of other previously identified coiled
bodies in the nucleus [44]. The cellular localization of the
complex appears to be influenced by its interaction with unr-
interacting protein (Unrip), which directs localization to the
cytoplasm and is absent in nuclear gems [49]. SMN appears to
have many different functions, including roles in small nuclear
ribonucleoprotein (snRNP) assembly and pre-mRNA splicing
[50], translational regulation [51], R-loop resolution [52],
transport of β-actin mRNA and secretion vesicles [53,54], and
regulation of actin dynamics [55,56] (Table 2).
Although there is accumulating evidence that SMA is more
than simply a disease of motor neurons, most studies in mouse
models of SMA have focused on the effect of reduced levels of
SMN on motor neuron function. These effects include altered
splicing of many genes [50,72–74], poor terminal arborization
[58], aggregation of neurofilaments in the motor end plate [58],
impaired synaptic vesicle release [75], reduced neuromuscular
junction plasticity [76] and, ultimately, denervation and death of
the motor neuron [77]. All of these defects occur very early
during disease progression, indicating that abnormal motor
neuron structure and function are an early hallmark of the
disease.
Although α-motor neurons are most affected in SMA, recent
studies have shown that other tissues are also affected [78]
(Table 2). Reduced levels of SMN in pre-symptomatic mice
are associated with muscle weakness, and a delay in the
appearance of mature isoforms of proteins important for muscle
contractions [63]. Low levels of SMN cause muscle satellite
cell defects, which manifests as the aberrant initiation of the
differentiation program and reduced efficiency of myotube
formation [62,63,79,80]. Similar observations were found in
studies with myoblasts from patient with SMA [81]. Several
studies have described cardiac muscle defects in mouse models
of SMA [67–69], which are also observed in severe human
disease [82]. Recently, defects in glucose metabolism and
pancreatic function have been detected in SMA mice [64].
Indeed, heterozygous Smn +/− mice (mice naturally only have
one copy of the Smn gene [12]) display defects in pancreas
development and aberrant glucose metabolism, in the absence
of any SMA-like disease, suggesting SMN may represent a
diabetes susceptibility locus [65,83]. A recent study showed
that reduced levels of SMN impact the ability of astrocytes
to perform their normal functions of supporting neuron
development and synapse formation [59]. Astrogliosis is
Table 2
Functions of SMN protein.
Function SMA disease manifestation
Molecular function
Small nuclear ribonucleoprotein (snRNP)
assembly and pre-mRNA splicing
Reduced snRNP assembly and altered splicing pattern of many genes in brain and spinal cord [50]
Translational regulation Altered protein translation (e.g. CARM1 [51])
R-loop resolution Alterations in cellular gene expression and splicing [52]
Active transport Altered transport of β-actin mRNA to motor neuron growth cones [53]; altered transport of
Golgi-associated secretion vesicles [54]
Actin dynamics Inappropriate activation of the RhoA/ROCK pathway perturbs actin dynamics [55,56]
Biological function
Motor neuron outgrowth and axonal pathfinding Impaired motor neuron connections in zebrafish [57]
Neuromuscular junction function and maturation Abnormal endplate morphology, endplate denervation, neurofilament accumulation and disturbed function,
impaired astrocyte and Schwann cell function [58–61]
Muscle development Impaired satellite cell differentiation [62]; muscle weakness and delay in expression of mature proteins [63]
Pancreas development Reduced β cell numbers leading to defective glucose metabolism [64,65]
Liver function Altered expression of IGFALS leading to reduced stability of IGF-1 and stunted growth [66]
Autonomic nervous system Cardiac defects and bradycardia [67–69]; vasodilation defects [70,71]
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evident in end-stage SMA mice and in post-mortem patient
spinal cords, and restoration of SMN specifically in astrocytes
of SMAmice increased lifespan, improved motor unit function,
and normalized neuromuscular junction defects. Intrinsic
defects were also observed in Schwann cells deficient in SMN,
which included reduced ability to myelinate neurons [60].
However, although restoration of SMN exclusively in Schwann
cells did reverse the myelination defects in a mouse model of
SMA, motor neuron survival was not improved [84]. Taken
together, these studies demonstrate that although SMA may be
considered primarily a disease of α-motor neurons, there are
deficiencies that arise in other types of neurons, muscle, liver
and pancreas that may contribute to the disease state. Since
patients with SMA are now living longer due to improved
assistive technology, these recently identified “secondary”
deficiencies need to be more closely examined to evaluate their
impact on the clinical course of SMA. Furthermore, truly
effective therapies may need to restore SMN levels body-wide
to achieve a complete beneficial effect.
4. Emerging therapies for SMA and the
therapeutic window
Given the prevalence and potential severity of SMA,
numerous research groups are working to identify novel therapies
for this devastating disease (for review, please see References
[78,85,86]). There are three broad areas to which therapies can be
directed, including (1) correct the aberrant splicing of the SMN2
gene product or stabilize the SMNΔ7 protein; (2) target the
downstream damage caused by SMN deficiency by protecting
affected tissues from death; or (3) reintroduce the missing
SMN1 gene or its gene product using a therapeutic vector.
Within each of these strategies, there exists a wide variety of
therapeutics in development (Table 3), some of which have
entered clinical trials. For example, an antisense oligonucleotide
therapeutic developed by IONIS Pharmaceuticals (formerly ISIS
Pharmaceuticals) and Biogen Idec designed to block splicing-out
of exon 7 from the SMN2 transcript, has completed a phase I
clinical trial in 28 patients [87,88]. The agent was well tolerated
and appeared to improve motor function in some of the treated
patients. In the follow-up open-label Phase II study of children
with SMA, IONIS observed a time- and dose-dependent increase
in muscle function scores in children treated with multiple-doses
of their lead oligonucleotide ISIS-SMNRx or nusinersen [89]. No
severe adverse events were reported. Nusinersen efficacy is
currently being assessed in a Phase III clinical trial [90]. A
self-complementary adeno-associated viral vector based on
serotype 9 (sc-AAV9) encoding a full-length copy of the SMN1
cDNA, which showed very promising results in mouse models of
SMA [91], is currently in Phase I/II clinical trial in children with
SMAType I [92]. Preliminary results from this study showed that
the vector, AVXS-101, appears to be generally safe and well
tolerated in the nine patients studied to date, and all patients
experienced an improvement in motor function [93]. Thus, at
least two therapies are showing promise in clinical trials for
SMA.
A central theme that has emerged from preclinical studies of
novel therapies in SMA mice is the importance of early
intervention to achieve maximal therapeutic benefit. Antisense
oligonucleotides that rescue the phenotype in SMAmodel mice
must be administered in utero or immediately upon birth to
achieve the greatest beneficial effect [66,94,95]. Similarly,
studies utilizing the scAAV9-SMN1 showed that the vector had
to be delivered very soon after birth of the affected mice in
order to achieve a therapeutic benefit and extend mouse
survival [91]. The therapeutic window for severe SMA in
human patients is believed to be early and narrow, to prevent the
rapid degeneration of the α-motor neurons and other affected
tissues. Therefore, early detection is essential to identify
candidates for the many therapeutics currently approaching or
entering the clinic [3,96,97].
Table 3
Therapeutic strategies for treating SMA.
Category Sub-class Mode of action Agent
SMN2
targeting
Histone deacetylase inhibition Increases transcription and/or splicing Valproic acid, sodium butyrate, trichostatin A,
SAHA, LBH589
Counteract DNA methylation Reduces silencing of SMN2 Romidepsin, vorinostat
Promoter activation Increase transcription of SMN2 Prolactin, quinazalone 495
Antisense oligonucleotide Alter SMN2 pre-mRNA splicing Pro-105, ASO-10-27
Bifunctional RNA Recruit splicing factors to optimize splicing of SMN2 Various
Trans-splicing Provide a splice acceptor and SMN1 exon 7 Various
Drugs affecting SMN2
pre-mRNA splicing
Promote SMN2 pre-mRNA splicing to include exon 7 Hydroxyurea, PTK-SMA1, albuterol/salbutamol,
aclarubicin
Reduce protein turnover Enhance protein stability or reduce degradation Bortezomib
Aminoglycosides Promotes read-through of SMN2 exon 8, creating
a more stable protein
G418, TC007, tobramycin, amikacin
Non-SMN
targeting
Regulation of actin dynamics Rho kinase inhibition Y-27632, fasudil
Regulation of actin dynamics Enhance axonogenesis through increasing F-actin levels Plastin 3
Enhance muscle strength Myostatin inhibition Follistatin, tirasemtiv
Protect motor neurons Neurotrophic factor Cardiotrophin-1, β-lactam, IGF-1
Replacement
of SMN1
Gene replacement Replace endogenous gene Vector-mediated delivery of a cDNA copy of SMN1
Stem cell therapies Differentiate into motor neurons to replace lost cells
or provide neuroprotective functions
Neural stem cells, embryonic stem cell-derived
neural stem cells
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5. Genetic screening for SMA: cost versus benefit
5.1. Genetic testing and carrier screening
Considering the brevity of the therapeutic window for
patients with the most severe form of SMA, early detection of
SMA will likely be essential to the success of any therapeutic
regimen. Although the merit of universal prenatal/neonatal
screening for SMA is currently being debated, carrier screening
is presently performed for parents of an affected child in an
attempt to predict the risk of recurrence in future children [98].
In addition to confirming their carrier status, parents of an
affected child are assessed for their SMN2 copy number in an
effort to predict the severity of SMA and prognosis in a
potentially affected child, although, as discussed above, there is
an imperfect correlation between SMN2 copy number and
disease prognosis.
There are a number of methods available to screen DNA for
SMN1 deletion or SMN2 copy number (for an overview, please
see Reference [97]). Perhaps the most suitable screening
method among current technologies for hospital-based testing
is PCR/restriction enzyme digestion analysis. This method
allows for unambiguous detection of SMN1 deletion [99],
however, the method does not detect point mutations resulting
in functional loss of SMN1, and therefore additional diagnostic
tests are necessary when the carriers exhibit such mutations. An
emerging technology, which identifies SMN1 point mutations
and gene dosage of SMN2, is high resolution melting analysis
(HRMA) [100]. HRMA analysis is relatively quick, and
amenable to high throughput capabilities, which makes this
assay perhaps best suited for population-based screening. New
techniques such as whole exome or whole genome sequencing
are fundamentally changing the way novel disease-causing
genes are identified and patients diagnosed [101], and it is
likely that in the future these technologies will impact diagnosis
of SMA. However, currently these techniques are ineffective at
distinguishing SMN1 from SMN2 or SMN2 copy number.
5.2. The debate over population-based screening for SMA
There is debate regarding the utility of genetic screening
for SMA primarily due to the limitations of carrier screening
and the incurable status of the disease. Opponents of
population-based SMA screening cite the significant costs of
widespread screening [102], the potential for false negatives
in carrier testing [96], and the concern that carrier status
testing is only relevant for couples preparing to conceive a
child together. SMA carrier status does not affect the health of
the individual, and knowing that one is a carrier might affect
the decision to have children. The prospect of widespread
screening is also given pause by the absence of a cure for
the disease. Screening for SMN violates the second of ten
criteria adopted by the World Health Organization (WHO) in
1968 (the Wilson–Jungner criteria), which states that in order
for a genetic screen to be warranted, “there should be an
accepted treatment for patients with recognized disease”
[103]. The American Congress of Obstetricians and
Gynecologists (ACOG) cautions against such screening
particularly in the prenatal case, as improper understanding of
the variability in disease phenotype may lead to poorly
informed terminations of pregnancy [104].
Several groups have argued in favor of population-based
carrier screening. Due to the high carrier frequency and clinical
severity of the disease, the American College of Medical
Genetics (ACMG) recommends population-based SMA carrier
screening in addition to screening of all members of an affected
family [2]. The Muscular Dystrophy Association (MDA) has
advocated that genetic diseases for which new therapeutics are
entering clinical study, such as SMA, ought to be granted
priority in the review process used to determine which diseases
merit widespread newborn screening [105]. While it is true that
no accepted treatment for SMA currently exists, early detection
of SMA by a prenatal/neonatal screen could improve quality of
life for the patient by allowing the parents to anticipate
immediate health needs and prepare for the proper medical care
of the affected child [106].
A recent reassessment of the Wilson–Jungner criteria
published by the WHO recognized the benefits of genetic
screening for disease which lack an accepted treatment, and a
new set of tentative criteria was generated based on this
consideration and on other new developments in genomics
[107]. This new set of criteria does not require a specific
established treatment for a disease, but instead requires an
established need for the screen, a clear target population, and
the integration of patient education in the screening program,
none of which is an obstacle to SMA screening [107].
Considering these more modern ethical criteria and the current
state of screening technology, widespread screening for SMA
certainly warrants further discussion.
5.3. Financial cost of SMA
Cost of illness (also referred to as burden of disease) refers
to the financial burden incurred by the patient, the patient’s
family, and insurance companies to fund treatment of the
disease and non-medical accommodations related to the illness.
A recent study by the Lewin group, funded by the MDA,
evaluated the annual cost of illness of several muscular
disorders including hereditary progressive muscular dystrophy
(HPMD), myotonic dystrophy (MMD), congenital muscular
dystrophy (CMD), amyotrophic lateral sclerosis (ALS), and
SMA [108,109]. Patients with SMA were not separated by
disease type, but instead were divided into patients whose
disease onset occurred prior to three years of age (SMA Early
Onset) or later (SMAOther). The mean medical expenditure for
privately insured patients in the SMA Early Onset category was
$121,682 USD annually (all numbers are given in US dollars),
substantially higher than the means for the other diseases
(CMD was second highest with $32,341). However, the sample
size for the SMA Early Onset category was small and there
was considerable variability between patients (standard
error = $98,898, n = 14). Since many patients who experience
early onset of SMA exhibit type 1 disease, the severity of the
disease and the acute medical attention required for these
patients may account for such high medical expenses. Mean
annual medical costs for patients in the SMA Other category
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were lower ($20,085, standard error = $1,811), but similar to
the other muscular diseases [108,109].
In addition to funds spent on direct medical diagnosis and
treatment, patients with SMA and their families may incur
non-medical expenses, such as wage loss, caregiver salaries and
cost of assistive devices to enhance the patient’s mobility and
independence. An important cost to consider is wages lost by
the patient or the patient’s family, particularly for the SMA
Early Onset group, in which 81.45% of patients required 16 or
more hours of attendance per day [108,109]. The estimated
annual loss of income for parents and guardians of patients with
early-onset SMA, with a weighted average which considers
wages lost and the time cost for sustained attendance of
the patient, is $35,623 (standard error = $2462), considerably
higher than the second highest wage loss ($19,217 for ALS).
The higher level of mobility associated with later onset of SMA
is expected to cause the lower wage loss in the SMA Other
group, with a mean loss of $11,110 (standard error = $627).
The authors reported the mean annual cost for other non-
medical expenditures, including home modifications, vehicle
modifications, and non-medical professional care. Annual costs
for each patient were obtained by dividing the total non-medical
costs over the patient’s life by the number of years the patient
was affected. Again, the mean cost was highest for the SMA
Early Onset group at $51,665, but these costs varied
significantly between patients and the sample size was again
small (standard error = $39,501, n = 17). The majority of these
funds were used to pay professional caregivers. Patients in the
SMA Other group averaged $14,295 for non-medical expenses
(standard error = $1651), which was similar to the costs
incurred by the other muscular diseases [108,109].
Finally, the Lewin group estimated total national cost of
illness in the United States for each disease by multiplying the
per capita medical expense by three estimations of disease
prevalence in the country. Using the moderate estimations for
disease prevalence, this yields a total medical cost of $684
million annually for early-onset SMA and $273 million for
SMA with an onset of later than three years [108,109]. Since
SMA occurs at a similar rate across ethnicities [110], these
costs can be expected to be proportionately similar in other
countries, although costs of medical services will vary by
country. Obviously, the significant medical and supportive costs
incurred in caring for patients with SMA underscore the need
for effective therapeutics and early intervention.
5.4. Cost effectiveness of SMA screening
In order to assess the cost effectiveness of prenatal SMA
screening, Little et al. developed a theoretical model comparing
universal screening to complete absence of screening using
values derived from literature [102]. This study took into
account expenses such as carrier testing, amniocentesis, fetal
testing, and pregnancy termination in instances of a positive
fetal test, versus the total lifetime cost of caring for a child with
severe or mild disease. The authors also took into account
maternal quality-adjusted life years (QALYs), a measure of
disease burden on quality of life lived. Little et al. estimated the
total cost of universal screening to be $44 million per 100,000
women, or approximately $5 million per SMA case averted. In
contrast, the total cost for treating the 10 affected children (per
100,000 women) predicted to be born in the absence of
screening would be about $4.7 million. The authors ultimately
concluded that universal prenatal screening was not cost
effective; however, their study suggested that for populations at
high risk, such as those with a family history of SMA, carrier
testing may still be a cost-effective strategy.
6. Final perspective
Spinal muscular atrophy can cause tremendous suffering –
physical, financial, and emotional – to the patient and the family
of the affected individual. Currently, from an economic
perspective, universal testing for SMA does not appear a viable
choice. However, testing of individuals at high risk, such as
those with a family history of SMA, is prudent.A positive result
from carrier screening in parents can lead to prenatal screening
of the child. An unborn child confirmed to have homozygous
deletion or mutation in SMN1 can be tested for SMN2 gene
dosage. Although SMN2 gene dosage is not a perfect predictor
of SMA disease type, given proper counseling and support, the
family of an affected child could consider the probability of
their child being born with severe disease and tailor their
response accordingly. This information would assist the parents
in making an informed decision in the unfortunate event that
the prognosis for their unborn child is extremely poor, or make
appropriate preparations, both practically and emotionally,
for a child whose life expectancy is normal, but will require
additional attendance and assistance with mobility.
SMA currently has no effective treatment or cure, but
several experimental therapeutics have reached advanced stage
of clinical testing in human patients. All available data from
studies in animal models of SMA have suggested that
maximum benefit is achieved only when the therapy is initiated
prior to overt loss of motor neurons. It is logical to assume that
the same will occur in human patients, indicating that early
detection of SMA is desirable either to initiate therapy very
soon after birth, or perhaps even in utero in the case of a child
with severe SMA. Prenatal screening will identify affected
children before the closure of the therapeutic window, allowing
these patients to be treated with emerging SMA therapeutics.
Any argument for or against prenatal or neonatal screening
for SMA that is based solely on economics has not taken into
account the very legitimate issues of parent preparedness and
potential for early therapeutic intervention. As technology
progresses, and the cost of screening for SMA becomes less
and new therapeutics become available, it will be important to
readdress the need for SMA screening. Although SMA is
presently incurable, prenatal or neonatal screening will be a
boon to quality of life for patients and a crucial catalyst for the
development of treatments and possibly a cure.
Acknowledgements
Research in the Parks laboratory is supported by grants
from the Canadian Institutes of Health Research (CIHR)
(MOP-130279 to R.K.; ERL-138414 to R.K.; MOP-136898 to
556 J.K. Burns et al. /Neuromuscular Disorders 26 (2016) 551–559
R.J.P.; MOP-142316 to R.J.P.), the Natural Sciences and
Engineering Research Council of Canada (NSERC) (RGPIN-
2014-04810 to R.J.P.), and the Cancer Research Society
(Canada) (19363 to R.J.P.). Research in the Kothary laboratory
is supported by grants from CIHR, the Muscular Dystrophy
Association (USA) (294568 to R.K.), Cure SMA/Families of
SMA Canada (KOT1617 to R.K.), and the Multiple Sclerosis
Society of Canada (EGID2098 to R.K.). J.K.B. was supported
by the Queen Elizabeth II Graduate Scholarship in Science and
Technology from the Government of Ontario. R.K. is a
recipient of a University Health Research Chair from the
University of Ottawa. We thank Drs. Jane Larkindale, Dennis
Bulman (Children’s Hospital of Eastern Ontario Research
Institute) and Jodi Warman Chardon (The Ottawa Hospital) for
providing data and insight for this review.
References
[1] Crawford TO, Pardo CA. The neurobiology of childhood spinal
muscular atrophy. Neurobiol Dis 1996;3:97–110.
[2] Prior TW. Carrier screening for spinal muscular atrophy. Genet Med
2008;10:840–2.
[3] Nurputra DK, Lai PS, Harahap NI, et al. Spinal muscular atrophy:
from gene discovery to clinical trials. Ann Hum Genet 2013;77:
435–63.
[4] Shababi M, Lorson CL, Rudnik-Schoneborn SS. Spinal muscular
atrophy: a motor neuron disorder or a multi-organ disease? J Anat
2014;224:15–28.
[5] Boyer JG, Bowerman M, Kothary R. The many faces of SMN:
deciphering the function critical to spinal muscular atrophy
pathogenesis. Future Neurol 2010;5:873–90.
[6] Rudnik-Schoneborn S, Stolz P, Varon R, et al. Long-term observations
of patients with infantile spinal muscular atrophy with respiratory
distress type 1 (SMARD1). Neuropediatrics 2004;35:174–82.
[7] Lefebvre S, Bürglen L, Reboullet S, et al. Identification and
characterization of a spinal muscular atrophy-determining gene. Cell
1995;80:155–65.
[8] Hahnen E, Forkert R, Marke C, et al. Molecular analysis of candidate
genes on chromosome 5q13 in autosomal recessive spinal muscular
atrophy: evidence of homozygous deletions of the SMN gene in
unaffected individuals. Hum Mol Genet 1995;4:1927–33.
[9] Rochette CF, Surh LC, Ray PN, et al. Molecular diagnosis of
non-deletion SMA patients using quantitative PCR of SMN exon 7.
Neurogenetics 1997;1:141–7.
[10] Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the
SMN gene regulates splicing and is responsible for spinal muscular
atrophy. Proc Natl Acad Sci USA 1999;96:6307–11.
[11] Jodelka FM, Ebert AD, Duelli DM, Hastings ML. A feedback loop
regulates splicing of the spinal muscular atrophy-modifying gene,
SMN2. Hum Mol Genet 2010;19:4906–17.
[12] Schrank B, Gotz R, Gunnersen JM, et al. Inactivation of the survival
motor neuron gene, a candidate gene for human spinal muscular atrophy,
leads to massive cell death in early mouse embryos. Proc Natl Acad Sci
USA 1997;94:9920–5.
[13] Hsieh-Li H, Chang JG, Jong YJ, et al. A mouse model for spinal
muscular atrophy. Nat Genet 2000;24:66–70.
[14] Lefebvre S, Burlet P, Liu Q, et al. Correlation between severity and SMN
protein level in spinal muscular atrophy. Nat Genet 1997;16:265–9.
[15] Coovert DD, Le TT, McAndrew PE, et al. The survival motor neuron
protein in spinal muscular atrophy. Hum Mol Genet 1997;6:1205–14.
[16] Lim SR, Hertel KJ. Modulation of survival motor neuron pre-mRNA
splicing by inhibition of alternative 3′ splice site pairing. J Biol Chem
2001;276:45476–83.
[17] Hofmann Y, Lorson CL, Stamm S, Androphy EJ, Wirth B. Htra2-Beta1
stimulates an exonic splicing enhancer and can restore full-length SMN
expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci USA
2000;97:9618–23.
[18] Hofmann Y, Wirth B. hnRNP-G promotes exon 7 inclusion of survival
motor neuron (SMN) via direct interaction with Htra2-Beta1. Hum Mol
Genet 2002;11:2037–49.
[19] Cartegni L, Krainer AR. Disruption of an SF2/ASF-dependent exonic
splicing enhancer in SMN2 causes spinal muscular atrophy in the
absence of SMN. Nat Genet 2002;30:377–84.
[20] Kashima T, Manley JL. A negative element in SMN2 exon 7 inhibits
splicing in spinal muscular atrophy. Nat Genet 2003;34:460–3.
[21] Pedrotti S, Bielli P, Paronetto MP, et al. The splicing regulator Sam68
binds to a novel exonic splicing silencer and functions in SMN2
alternative splicing in spinal muscular atrophy. EMBO J 2010;29:
1235–47.
[22] Singh NN, Singh RN, Androphy EJ. Modulating role of RNA structure
in alternative splicing of a critical exon in the spinal muscular atrophy
genes. Nucleic Acids Res 2007;35:371–89.
[23] Miyajima H, Miyaso H, Okumura M, Kurisu J, Imaizumi K.
Identification of a cis-acting element for the regulation of SMN exon 7
splicing. J Biol Chem 2002;277:23271–7.
[24] Miyaso H, Okumura M, Kondo S, Higashide S, Miyajima H, Imaizumi
K. An intronic splicing enhancer element in survival motor neuron
(SMN) pre-mRNA. J Biol Chem 2003;278:15825–31.
[25] Kashima T, Rao N, Manley JL. An intronic element contributes to
splicing repression in spinal muscular atrophy. Proc Natl Acad Sci USA
2007;104:3426–31.
[26] Russman BS. Spinal muscular atrophy: clinical classification and disease
heterogeneity. J Child Neurol 2007;22:946–51.
[27] Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative
analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast
and highly reliable carrier testing and prediction of severity of spinal
muscular atrophy. Am J Hum Genet 2002;70:358–68.
[28] Dubowitz V. Chaos in classification of the spinal muscular atrophies of
childhood. Neuromuscul Disord 1991;1:77–80.
[29] Dubowitz V. Chaos in the classification of SMA: a possible resolution.
Neuromuscul Disord 1995;5:3–5.
[30] Thomas NH, Dubowitz V. The natural history of type I (severe) spinal
muscular atrophy. Neuromuscul Disord 1994;4:497–502.
[31] Lunn MR, Wang CH. Spinal muscular atrophy. Lancet 2008;371:
2120–33.
[32] Dubowitz V. Ramblings in the history of spinal muscular atrophy.
Neuromuscul Disord 2009;19:69–73.
[33] Russman BS, Iannacone ST, Buncher CR, et al. Spinal muscular
atrophy: new thoughts on the pathogenesis and classification schema.
J Child Neurol 1992;7:347–53.
[34] Russman BS, Melchreit R, Drennan JC. Spinal muscular atrophy: the
natural course of disease. Muscle Nerve 1983;6:179–81.
[35] Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of
spinal muscular atrophy type I and implications for clinical trials.
Neurology 2014;83:810–17.
[36] Kaufmann P, McDermott MP, Darras BT, et al. Prospective cohort
study of spinal muscular atrophy types 2 and 3. Neurology 2012;79:
1889–97.
[37] Kaufmann P, McDermott MP, Darras BT, et al. Observational study of
spinal muscular atrophy type 2 and 3: functional outcomes over 1 year.
Arch Neurol 2011;68:779–86.
[38] Moulard B, Salachas F, Chassande B, et al. Association between
centromeric deletions of the SMN gene and sporadic adult-onset lower
motor neuron disease. Ann Neurol 1998;43:640–4.
[39] Crawford TO, Paushkin SV, Kobayashi DT, et al. Evaluation of SMN
protein, transcript, and copy number in the biomarkers for spinal
muscular atrophy (BforSMA) clinical study. PLoS ONE 2012;7:e33572.
[40] Brkusanin M, Kosac A, Jovanovic V, et al. Joint effect of the SMN2 and
SERF1A genes on childhood-onset types of spinal muscular atrophy in
Serbian patients. J Hum Genet 2015;60(11):723–8.
[41] Stratigopoulos G, Lanzano P, Deng L, et al. Association of plastin 3
expression with disease severity in spinal muscular atrophy only in
postpubertal females. Arch Neurol 2010;67:1252–6.
557J.K. Burns et al. /Neuromuscular Disorders 26 (2016) 551–559
[42] Oprea GE, Krober S, McWhorter ML, et al. Plastin 3 is a protective
modifier of autosomal recessive spinal muscular atrophy. Science
2008;320:524–7.
[43] McGovern VL, Massoni-Laporte A, Wang X, et al. Plastin 3 expression
does not modify spinal muscular atrophy severity in the 7 SMA mouse.
PLoS ONE 2015;10:e0132364.
[44] Liu Q, Dreyfuss G. A novel nuclear structure containing the survival of
motor neurons protein. EMBO J 1996;15:3555–65.
[45] Fischer U, Liu Q, Dreyfuss G. The SMN-SIP1 complex has an essential
role in spliceosomal snRNP biogenesis. Cell 1997;90:1023–9.
[46] Lorson CL, Strasswimmer J, Yao JM, et al. SMN oligomerization defect
correlates with spinal muscular atrophy severity. Nat Genet 1998;19:
63–6.
[47] Burnett BG, Munoz E, Tandon A, Kwon DY, Sumner CJ, Fischbeck KH.
Regulation of SMN protein stability. Mol Cell Biol 2009;29:1107–15.
[48] Kolb SJ, Battle DJ, Dreyfuss G. Molecular functions of the SMN
complex. J Child Neurol 2007;22:990–4.
[49] Grimmler M, Otter S, Peter C, Muller F, Chari A, Fischer U. Unrip, a
factor implicated in cap-independent translation, associates with the
cytosolic SMN complex and influences its intracellular localization.
Hum Mol Genet 2005;14:3099–111.
[50] Zhang Z, Lotti F, Dittmar K, et al. SMN deficiency causes tissue-specific
perturbations in the repertoire of snRNAs and widespread defects in
splicing. Cell 2008;133:585–600.
[51] Sanchez G, Dury AY, Murray LM, et al. A novel function for the survival
motoneuron protein as a translational regulator. Hum Mol Genet
2013;22:668–84.
[52] Zhao DY, Gish G, Braunschweig U, et al. SMN and symmetric arginine
dimethylation of RNA polymerase II C-terminal domain control
termination. Nature 2016;529:48–53.
[53] Rossoll W, Jablonka S, Andreassi C, et al. SMN, the spinal muscular
atrophy-determining gene product, modulates axon growth and
localization of beta-actin mRNA in growth cones of motoneurons. J Cell
Biol 2003;163:801–12.
[54] Ting CH, Wen HL, Liu HC, Hsieh-Li HM, Li H, Lin-Chao S. The spinal
muscular atrophy disease protein SMN is linked to the Golgi network.
PLoS ONE 2012;7:e51826.
[55] BowermanM, Anderson CL, Beauvais A, Boyl PP, Witke W, Kothary R.
SMN, profilin IIa and plastin 3: a link between the deregulation
of actin dynamics and SMA pathogenesis. Mol Cell Neurosci
2009;42:66–74.
[56] Bowerman M, Beauvais A, Anderson CL, Kothary R. Rho-kinase
inactivation prolongs survival of an intermediate SMA mouse model.
Hum Mol Genet 2010;19:1468–78.
[57] Zhang HL, Pan F, Hong D, Shenoy SM, Singer RH, Bassell GJ. Active
transport of the survival motor neuron protein and the role of exon-7 in
cytoplasmic localization. J Neurosci 2003;23:6627–37.
[58] Kariya S, Park GH, Maeno-Hikichi Y, et al. Reduced SMN protein
impairs maturation of the neuromuscular junctions in mouse models of
spinal muscular atrophy. Hum Mol Genet 2008;17:2552–69.
[59] Rindt H, Feng Z, Mazzasette C, et al. Astrocytes influence the severity of
spinal muscular atrophy. Hum Mol Genet 2015;24:4094–102.
[60] Hunter G, Aghamaleky Sarvestany A, Roche SL, Symes RC,
Gillingwater TH. SMN-dependent intrinsic defects in Schwann cells in
mouse models of spinal muscular atrophy. Hum Mol Genet 2014;23:
2235–50.
[61] Murray LM, Comley LH, Thomson D, Parkinson N, Talbot K,
Gillingwater TH. Selective vulnerability of motor neurons and
dissociation of pre- and post-synaptic pathology at the neuromuscular
junction in mouse models of spinal muscular atrophy. Hum Mol Genet
2008;17:949–62.
[62] Hayhurst M, Wagner AK, Cerletti M, Wagers AJ, Rubin LL. A
cell-autonomous defect in skeletal muscle satellite cells expressing
low levels of survival of motor neuron protein. Dev Biol 2012;368:
323–34.
[63] Boyer JG, Murray LM, Scott K, De Repentigny Y, Renaud JM, Kothary
R. Early onset muscle weakness and disruption of muscle proteins in
mouse models of spinal muscular atrophy. Skelet Muscle 2013;3:24.
[64] BowermanM, Swoboda KJ, Michalski JP, et al. Glucose metabolism and
pancreatic defects in spinal muscular atrophy. Ann Neurol 2012;72:
256–68.
[65] Bowerman M, Michalski JP, Beauvais A, Murray LM, DeRepentigny Y,
Kothary R. Defects in pancreatic development and glucose metabolism
in SMN-depleted mice independent of canonical spinal muscular
atrophy neuromuscular pathology. Hum Mol Genet 2014;23:3432–44.
[66] Hua Y, Sahashi K, Rigo F, et al. Peripheral SMN restoration is essential
for long-term rescue of a severe spinal muscular atrophy mouse model.
Nature 2011;478:123–6.
[67] Bevan AK, Hutchinson KR, Foust KD, et al. Early heart failure in the
SMNDelta7 model of spinal muscular atrophy and correction by
postnatal scAAV9-SMN delivery. Hum Mol Genet 2010;19:3895–905.
[68] Shababi M, Habibi J, Ma L, Glascock JJ, Sowers JR, Lorson CL. Partial
restoration of cardio-vascular defects in a rescued severe model of spinal
muscular atrophy. J Mol Cell Cardiol 2012;52:1074–82.
[69] Gogliotti RG, Quinlan KA, Barlow CB, Heier CR, Heckman CJ,
Didonato CJ. Motor neuron rescue in spinal muscular atrophy mice
demonstrates that sensory-motor defects are a consequence, not a cause,
of motor neuron dysfunction. J Neurosci 2012;32:3818–29.
[70] Hachiya Y, Arai H, Hayashi M, et al. Autonomic dysfunction in cases
of spinal muscular atrophy type 1 with long survival. Brain Dev
2005;27:574–8.
[71] Araujo A, Araujo M, Swoboda KJ. Vascular perfusion abnormalities in
infants with spinal muscular atrophy. J Pediatr 2009;155:292–4.
[72] Pellizzoni L, Kataoka N, Charroux B, Dreyfuss G. A novel function for
SMN, the spinal muscular atrophy disease gene product, in pre-mRNA
splicing. Cell 1998;95:615–24.
[73] Liu H, Shafey D, Moores JN, Kothary R. Neurodevelopmental
consequences of Smn depletion in a mouse model of spinal muscular
atrophy. J Neurosci Res 2010;88:111–22.
[74] Lotti F, Imlach WL, Saieva L, et al. An SMN-dependent U12 splicing
event essential for motor circuit function. Cell 2012;151:440–54.
[75] Kong L, Wang X, Choe DW, et al. Impaired synaptic vesicle release and
immaturity of neuromuscular junctions in spinal muscular atrophy mice.
J Neurosci 2009;29:842–51.
[76] Murray LM, Beauvais A, Bhanot K, Kothary R. Defects in
neuromuscular junction remodelling in the Smn2B/- mouse model of
spinal muscular atrophy. Neurobiol Dis 2013;49:57–67.
[77] McGovern VL, Gavrilina TO, Beattie CE, Burghes AH. Embryonic
motor axon development in the severe SMA mouse. Hum Mol Genet
2008;17:2900–9.
[78] Goulet BB, Kothary R, Parks RJ. At the “junction” of spinal muscular
atrophy pathogenesis: the role of neuromuscular junction dysfunction in
SMA disease progression. Curr Mol Med 2013;13:1160–74.
[79] Bricceno KV, Martinez T, Leikina E, et al. Survival motor neuron
protein deficiency impairs myotube formation by altering myogenic gene
expression and focal adhesion dynamics. Hum Mol Genet 2014;23:
4745–57.
[80] Boyer JG, Deguise MO, Murray LM, et al. Myogenic program
dysregulation is contributory to disease pathogenesis in spinal muscular
atrophy. Hum Mol Genet 2014;23:4249–59.
[81] Martinez-Hernandez R, Soler-Botija C, Also E, et al. The developmental
pattern of myotubes in spinal muscular atrophy indicates prenatal
delay of muscle maturation. J Neuropathol Exp Neurol 2009;68:
474–81.
[82] Rudnik-Schoneborn S, Heller R, Berg C, et al. Congenital heart disease
is a feature of severe infantile spinal muscular atrophy. J Med Genet
2008;45:635–8.
[83] Davis RH, Miller EA, Zhang RZ, Swoboda KJ. Responses to fasting and
glucose loading in a cohort of well children with spinal muscular atrophy
type II. J Pediatr 2015;167:1362–8, e1.
[84] Hunter G, Powis RA, Jones RA, et al. Restoration of SMN in Schwann
cells reverses myelination defects and improves neuromuscular function
in spinal muscular atrophy. Hum Mol Genet 2016;doi:10.1093/
hmg/ddw141.
[85] d’Ydewalle C, Sumner CJ. Spinal muscular atrophy therapeutics: where
do we stand? Neurother 2015;12:303–16.
558 J.K. Burns et al. /Neuromuscular Disorders 26 (2016) 551–559
[86] Faravelli I, Nizzardo M, Comi GP, Corti S. Spinal muscular
atrophy–recent therapeutic advances for an old challenge. Nat Rev
Neurol 2015;11:351–9.
[87] Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1
study of nusinersen (ISIS-SMNRx) in children with spinal muscular
atrophy. Neurology 2016;86:890–7.
[88] Hache M, Swoboda KJ, Sethna N, et al. Intrathecal injections in children
with spinal muscular atrophy: nusinersen clinical trial experience.
J Child Neurol 2016;31:899–906.
[89] IONIS-Pharmaceuticals. Isis pharmaceuticals reports data from
ISIS-SMN Rx phase 2 studies in infants and children with spinal
muscular atrophy, <http://ir.isispharm.com/phoenix.zhtml?c=222170&p
=irol-newsArticle&ID=1976144>; 2014 [accessed 27.05.15].
[90] ClinicalTrials.gov. A study to assess the efficacy and safety of ISIS-SMN
Rx in infants with spinal muscular atrophy, <https://clinicaltrials.gov/
ct2/show/NCT02193074?term=spinal+muscular+atrophy&rank=13>;
2015 [accessed 27.05.15].
[91] Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular
atrophy phenotype in a mouse model by early postnatal delivery of SMN.
Nat Biotechnol 2010;28:271–4.
[92] ClinicalTrials.gov. Gene transfer clinical trial for spinal muscular
atrophy type 1, <https://clinicaltrials.gov/ct2/show/NCT02122952?term
=NCT02122952&rank=1>; 2015 [accessed 27.05.15].
[93] Avexis. Data from ongoing study of AVXS-101 in spinal muscular
atrophy type 1, Presented at World Muscle Congress, <http://
investors.avexis.com/phoenix.zhtml?c=254285&p=irol-newsArticle&ID
=2127680>; 2015 [accessed 27.06.16].
[94] Hua Y, Sahashi K, Hung G, et al. Antisense correction of SMN2 splicing
in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev
2010;24:1634–44.
[95] Porensky PN, Mitrpant C, McGovern VL, et al. A single administration
of morpholino antisense oligomer rescues spinal muscular atrophy in
mouse. Hum Mol Genet 2012;21:1625–38.
[96] Prior TW, Snyder PJ, Rink BD, et al. Newborn and carrier screening for
spinal muscular atrophy. Obstet Gynecol Surv 2010;65:697–9.
[97] Phan HC, Taylor JL, Hannon H, Howell R. Newborn screening for spinal
muscular atrophy: anticipating an imminent need. Semin Perinatol
2015;39:217–29.
[98] Matthijs G, Devriendt K, Fryns JP. The prenatal diagnosis of spinal
muscular atrophy. Prenat Diagn 1998;18:607–10.
[99] van der Steege G, Grootscholten PM, van der Vlies P, et al. PCR-based
DNA test to confirm clinical diagnosis of autosomal recessive spinal
muscular atrophy 7. Lancet 1995;345:985–6.
[100] Chen WJ, Dong WJ, Lin XZ, et al. Rapid diagnosis of spinal muscular
atrophy using high-resolution melting analysis. BMC Med Genet
2009;10:45.
[101] Lek M, MacArthur D. The challenge of next generation sequencing in
the context of neuromuscular diseases. J Neuromuscul Dis 2014;1:
135–49.
[102] Little SE, Janakiraman V, Kaimal A, Musci T, Ecker J, Caughey AB.
The cost-effectiveness of prenatal screening for spinal muscular atrophy.
Am J Obstet Gynecol 2010;202:253, e1-7.
[103] Orzalesi M, Danhaive O. Ethical problems with neonatal screening. Ann
Ist Super Sanita 2009;45:325–30.
[104] ACOG. ACOG committee opinion no. 432: spinal muscular atrophy.
Obstet Gynecol 2009;113:1194–6.
[105] MDA. MDA’s board chairman advocates support for newborn
screening, [news article], 2013 March 7, <http://quest.mda.org/news/
mda-board-chairman-advocates-support-newborn-screening>; 2014
[accessed 27.06.16].
[106] Swoboda KJ, Prior TW, Scott CB, et al. Natural history of denervation in
SMA: relation to age, SMN2 copy number, and function. Ann Neurol
2005;57:704–12.
[107] Andermann A, Blancquaert I, Beauchamp S, Dery V. Revisiting Wilson
and Jungner in the genomic age: a review of screening criteria over the
past 40 years. Bull World Health Organ 2008;86:317–19.
[108] MDA. Cost of amyotrophic lateral sclerosis, muscular dystrophy, and
spinal muscular atrophy in the United States. In: Muscular dystrophy
association sponsored study prepared by The Lewin Group. Tucson, AZ:
MDA; 2012. p. 1–54.
[109] Larkindale J, Yang W, Hogan PF, et al. Cost of illness for neuromuscular
diseases in the United States. Muscle Nerve 2014;49:431–8.
[110] Sugarman EA, Nagan N, Zhu H, et al. Pan-ethnic carrier screening
and prenatal diagnosis for spinal muscular atrophy: clinical
laboratory analysis of >72 400 specimens. Eur J Hum Genet
2012;20:27–32.
559J.K. Burns et al. /Neuromuscular Disorders 26 (2016) 551–559
